Investigation of radial dose distribution and cumulative dose of radiopharmaceuticals used for pain palliation of bone metastases

Ranjbar, Hassan; Bahrami-Samani, Ali; Beiki, Davood; GhanadiMaragheh, Mohammad

Document Type : Research Paper

Authors

Abstract

A cancer that begins in an organ, such as breast or prostate, and then spreads to the bone, results in metastatic bone. The treatment of the bone metastases is one of the most important challenges of nuclear medicine. Using radiopharmaceuticals has increased the hope for the cure or at least palliation of the bone metastases. The aim of this work is the comparison of the radial dose distribution and cumulative dose due to ¹⁵³Sm, ¹⁷⁷Lu and ¹⁶⁶Ho. Also, the side effects due to the energetic emitted particles of this radionuclide were evaluated. By the use of MCNPX computer code, a model was designed to calculate the absorbed dose in the bone phantom. The results showed that the maximum and minimum absorbed dose due to beta particles belong to ¹⁶⁶Ho and ¹⁷⁷Lu, respectively. The absorbed dose related to the ¹⁵³Sm gamma radiation is more than other radionuclides. Therefore, ¹⁶⁶Ho can be suitably used for treatment of the massive tumors and ¹⁷⁷Lu can be more useful for small tumors. ¹⁵³Sm is more reliable for tumors of differect sizes because of its medium energy radiation.

Keywords

References

[1] A.N. Serafini, Therapy of metastatic bone pain, J. Nucl. Med., 42 (2001) 895-906.

[2] J.A. Campa, R. Rayne, The management of intractable bone pain: a clinician’s perspective, Semin. Nucl. Med., 22 (1992) 3-10.

[3] J.F. Eary, C. Collin, M. Stabin, C. Vernon, S. Petersdorf, M. Baker, S. Hartnett, S. Ferency, S.J. Addison, F. Appelbaum, Samarium-153-EDTMP biodistribution and dosimetry estimation, J. Nucl. Med., 34 (1993) 1031-1036.

[4] A. Holmes, [153Sm]-EDTMP: a potential therapy for bone cancer, Semin. Nucl. Med., 22 (1992) 41-45.

[5] R.O. Robinson, D.F. Preston, J.A. Spicer, K.G. Baxter, Radionuclide therapy of intractable bone pain: Emphasis on Strontium-89, Semin. Nucl. Med., 22 (1992) 28-32.

[6] H.R. Maxon, S.R. Thomas, V.S. Hertzberg, L.E. Schroder, E.E. Englaro, R. Samaratunga, H.I. Scher, J.S. Moulton, E.A. Deutsch, K.F. Deutsch, H.J. Schneider, C.C. Williams, G.J. Ehrhardt, Rhenium-186-hydroxy-ethylidenediphosphonate for the treatment of painful osseous metastases, Semin. Nucl. Med., 22 (1992) 33-40.

[7] W.A. Volkert, T.J. Hoffman, Therapeutic radiopharmaceuticals, Chem. Rev., 99 (1999) 2269-2292.

[8] A. Bahrami-Samani, M. Ghannadi-Maragheh, A.R. Jalilian, S. Shirvani-Arani, M. Meftahi, S. Moradkhani, Production, quality control and biological evaluation of 153Sm-EDTMP in wild-type rodents, Iran J. Nucl. Med., 17 (2009) 12-19.

[9] H. Yousefnia, S. Zolghadri, A.R. Jalilian, M. Tajik, M. Ghannadi-Maragheh, Preliminary dosimetric evaluation of 166Ho-TTHMP for human based on biodistribution data in rats, Appl Radiat Isot., 94 (2014) 260-265.

[10] S. Zolghadri, A.R. Jalilian, H. Yousefnia, A. Bahrami-Samani, Y. Fazaeli, M. Pouladi, M. Ghannadi-Maragheh, H. Afarideh, The synthesis, radiolabeling and first biological evaluation of a new 166Ho-complex for radiotherapy of bone metastases, Radiochimica Acta., 101(7) (2013) 445-452.

[11] A. Bahrami-Samani, R. Bagheri, A.R. Jalilian, S. Shirvani-Arani, M. Ghannadi-Maragheh, M. Shamsaee, Production, quality control and pharmacokinetic studies of Ho-EDTMP for therapeutic applications, Sci Pharm., 78(3) (2010) 423-433.
[12] A.S. Shinto, D. Shibu, K.K. Kamaleshwaran, T. Das, S. Chakraborty, S. Banerjee, P. Thirumalaisamy, P. Das, G. Veersekar, 177Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases, J. Nucl. Med. Tech., 42 (2014) 55-61.

[13] A. Bahrami-Samani, A. Anvari, A.R. Jalilian, S. Shirvani-Arani, H. Yousefnia, M.R. Aghamiri, M. Ghannadi-Maragheh, Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials, Iran. J. Pharm. Res., 11(1) (2012) 137-144.

[14] J. Yuan, C. Liu, X. Liu, Y. Wang, D. Kuai, G. Zhang, J.J. Zaknun, Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study, Clin. Nucl. Med., 38(2) (2013) 88-92.

[15] N. Ayati, K. Aryana, A.R. Jalilian, T. Hoseinnejad, A. Bahrami Samani, Z. Ayati, F. Shariati, S.R. Zakavi, Treatment efficacy of 153Sm-EDTMP for painful bone metastasis, Asia. Oceania. J. Nucl. Med. Biol., 1 (2013) 27-31.

[16] M.S. Alavi, Clinical trial project: Lu-177- EDTMP for Bone Pain Palliation of Bone Metastasis in Breast Cancer [Project], Shiraz University of Medical Sciences, Nuclear Medicine Center, (2010).

[17] H. Ranjbar, A. Bahrami-Samani, D. Beiki, S. Shirvani-Arani, M. Ghannadi-Maragheh, Evaluation of 153Sm/177Lu-EDTMP mixture in wild-type rodents as a novel combined palliative treatment of bone pain agent, J. Radioanal. Nucl. Chem., (2014) 1-9.

[18] H.G. Hughes, W.H. Egdorf, F.C Gallmeier, J.S Hendricks, R.C Little, G.W. McKinney, R.E. Prael, T.L Roberts, E. Snow, L.S Waters, M.C White, MCNPX user’s manual, version 2.4.0. Report LA CP 02-408. Los Alamos, NM: Los Alamos National Laboratory, (2002).

[19] J.F. Briesmeister, MCNPTM–a general Monte Carlo Nparticle transport code: version 4C. Report LA-13709-M. Los Alamos, NM: Los Alamos National Laboratory, (2000).

[20] ICRU. Photon, electron, proton and neutron interaction data forbody tissues, ICRU Report 46, Bethesda, MD:ICRU;, (1992).

Journal of Nuclear Science, Engineering and Technology (JONSAT)

Investigation of radial dose distribution and cumulative dose of radiopharmaceuticals used for pain palliation of bone metastases

References

References

Volume 36, Issue 3 - Serial Number 73
December 2015
Pages 42-47

Investigation of radial dose distribution and cumulative dose of radiopharmaceuticals used for pain palliation of bone metastases

References

References

Volume 36, Issue 3 - Serial Number 73December 2015Pages 42-47

Volume 36, Issue 3 - Serial Number 73
December 2015
Pages 42-47